Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness

20 Sept 2022

Abstract excerpt

Abstract Background ER+ breast cancer (ER+ BC) is the most common subtype of BC. Recently, CDK4/6 inhibitors combined with aromatase inhibitors have been approved by FDA as the first‐line therapy for patients with ER+ BC, and showed promising therapeutic efficacy in clinical treatment. However, resistance to CDK4/6 inhibitors is frequently observed. A better understanding of the drug resistance mechanism is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36127291
DOI: 10.1111/cpr.13337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemnessPMID 36127291Read ↗

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seqSemantic proximity Read ↗

PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133+ cancer stem like cells.Semantic proximity Read ↗

PELP1/SRC-3-dependent regulation of metabolic kinases drives therapy resistant ER+ breast cancerSemantic proximity Read ↗

CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolismSemantic proximity Read ↗

Oncogene-induced senescence and senescence-associated secretory phenotype (SASP) determine the efficacy of palbociclib in PIK3CA mutated colorectal cancerSemantic proximity Read ↗

Targeting the MAPK signaling pathway: implications and prospects of flavonoids in 3P medicine as modulators of cancer cell plasticity and therapeutic resistance in breast cancer patientsSemantic proximity Read ↗

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity Read ↗

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsSemantic proximity Read ↗

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read ↗

Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast CancerSemantic proximity Read ↗

S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancerSemantic proximity Read ↗

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.